Generic Name and Formulations:
Alvimopan 12mg; hard-gelatin caps.
Merck & Co., Inc.
Indications for ENTEREG:
To accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection surgery with primary anastomosis.
Give 12mg 30mins to 5hrs before surgery, then 12mg twice daily starting on 1st post-op day until hospital discharge for up to 7 days; max 15 doses.
Opioid use, at therapeutic doses, for >7 consecutive days prior.
For short-term hospital use only. Potential risk of MI with long-term use. Severe hepatic impairment, ESRD, complete GI obstruction, pancreatic or gastric anastomosis: not recommended. Mild-to-severe renal impairment or mild-to-moderate hepatic impairment: monitor closely; discontinue if adverse reactions occur. Recent (within week prior to surgery) use of >3 doses of opioids; monitor for GI events. Japanese patients (monitor). Pregnancy (Cat.B). Nursing mothers.
Opioid antagonist (peripheral).
Available only to hospitals that enroll in Entereg Access Support and Education Program (EASE). For more information, and to enroll, call (877) 282-4786.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|